Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

UTSW Cancer Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation

Published: Tuesday, July 29, 2014
Last Updated: Monday, July 28, 2014
Bookmark and Share
Irreversible inhibitor for KRAS gene mutation involved in lung, colon, and pancreatic cancers.

UT Southwestern Medical Center cancer researchers have found a molecule that selectively and irreversibly interferes with the activity of a mutated cancer gene common in 30 percent of tumors.

The molecule, SML-8-73-1 (SML), interferes with the KRAS gene, or Kirsten rat sarcoma viral oncogene homolog. The gene produces proteins called K-Ras that influence when cells divide. Mutations in K-Ras can result in normal cells dividing uncontrollably and turning cancerous. These mutations are particularly found in cancers of the lung, pancreas, and colon. In addition, people who have the mutated gene are less responsive to therapy.

Researchers have unsuccessfully tried to develop a drug to inhibit K-Ras for some 30 years.

“RAS proteins including KRAS have not been ‘druggable’ for many decades despite a lot of effort from academia and industry,” said senior author Dr. Kenneth Westover, Assistant Professor of Radiation Oncology and Biochemistry, and a member of UT Southwestern’s Harold C. Simmons Cancer Center.

“We are exploring irreversible inhibitors as a solution, which we believe may pave the way for the development of KRAS-targeted compounds with therapeutic potential and perhaps compounds that target other RAS family proteins involved in cancer,” Dr. Westover said.

Dr. Westover works as both a clinician as a member of the Lung Radiation Oncology Team at the Simmons Cancer Center, and as a researcher. The Westover laboratory investigates the molecular basis of cancer with an eye toward developing compounds that perturb cancer biology, and therefore have potential to become therapies. Dr. Westover’s lab has been particularly targeting KRAS because this gene is the most commonly mutated oncogene in cancer.

Building on previous work, Dr. Westover and fellow investigators used a technique called X-ray crystallography to determine what happens when SML is added to KRAS carrying the G12C mutation, a hallmark of tobacco-associated lung cancer and present in 25,000 of the new cases of lung cancer in the U.S. annually.

Researchers found that SML irreversibly binds to mutated KRAS, making the KRAS G12C inactive. SML competes with molecules that KRAS naturally binds to, called GTP and GDP, and is not removable, even when GTP and GDP are present at very high levels. This attribute is what makes SML an irreversible inhibitor - neither GDP nor GTP are able to knock it off and take its place.

The researchers then used a technique called mass spectrometry to determine that SML is not only irreversible, but selective - binding only to KRAS and not the roughly 100 other members of the RAS protein family that have very similar structures.

“We believe SML may be the first irreversible and selective inhibitor of KRAS,” said Dr. Westover, who was recruited to UT Southwestern with funds from the state-funded Cancer Research and Prevention Institute of Texas. “As a next step, we are improving the SML compound to facilitate studies involving living cancer cells, and eventually animals and humans.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Saturday, October 10, 2015
UT Southwestern Biochemist Receives NIH Early Independence Award
Dr. William Israelsen studies on hibernation may aid the fight against cancer.
Wednesday, October 07, 2015
Researchers Discover Molecule that Accelerates Tissue Regeneration
Newly discovered molecule, SW033291 accelerate cell recovery following bone marrow transplants.
Friday, June 12, 2015
UT Southwestern Faculty Members Named HHMI Investigators
Appointment of Dr. Kim Orth and Dr. Joshua Mendell to HHMI.
Saturday, May 23, 2015
Scientists Identify Key Receptors Behind Development of AML
Blocking ITIM-receptor signaling in combination with conventional therapies may represent a novel strategy for AML treatment.
Saturday, May 02, 2015
Study Reveals Molecular Genetic Mechanisms Driving Breast Cancer Progression
The findings are published online and in the journal Molecular Cell.
Saturday, April 04, 2015
New Cyclotron Facility at UT Southwestern
Expands research opportunities and imaging capabilities for detecting, tracking cancer.
Friday, March 20, 2015
Acetate Supplements Shown to Speed Up Cancer Growth
A major compound produced in the gut by host bacteria.
Friday, February 20, 2015
MAGE Genes Provide Insight into Optimizing Chemotherapy
UT Southwestern Medical Center scientists have identified a new biomarker that could help identify patients who are more likely to respond to certain chemotherapies.
Tuesday, February 17, 2015
Researchers Identify ‘Achilles heel’ in Metabolic Pathway
Achilles heel could lead to new lung cancer treatments.
Saturday, February 14, 2015
Study Links Deficiency of Cellular Housekeeping Gene with Aggressive Forms of Breast Cancer
Research team studies genes involved in the autophagy process and their roles in cancer, aging, infections, and neurodegenerative diseases.
Saturday, January 31, 2015
Targeting The Cell’s ‘Biological Clock’
Researchers target the cell’s ‘biological clock’ in promising new therapy to kill cancer cells, shrink tumor growth.
Monday, January 05, 2015
Whole-Genome Sequencing Successfully Identifies Cancer-Related Mutations
UT Southwestern Medical Center cancer researchers have demonstrated that whole-genome sequencing can be used to identify patients’ risk for hereditary cancer.
Wednesday, December 24, 2014
Scientists Identify New and Beneficial Function of Endogenous Retroviruses
Researchers found that ERV play a critical role in the body’s immune defense against common bacterial and viral pathogens.
Friday, December 19, 2014
Signaling Mechanism Could Be Target For Survival, Growth Of Tumor Cells In Brain Cancer
Non-canonical EGFR signalling shown to make glioblastoma tumor cells more resistant to chemotherapy treatment.
Monday, December 15, 2014
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos